ダウンロード数: 172
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
ijms19041232.pdf | 964.79 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | Itatani, Yoshiro | en |
dc.contributor.author | Kawada, Kenji | en |
dc.contributor.author | Yamamoto, Takamasa | en |
dc.contributor.author | Sakai, Yoshiharu | en |
dc.contributor.alternative | 板谷, 喜朗 | ja |
dc.contributor.alternative | 河田, 健二 | ja |
dc.contributor.alternative | 坂井, 義治 | ja |
dc.date.accessioned | 2018-09-05T06:13:58Z | - |
dc.date.available | 2018-09-05T06:13:58Z | - |
dc.date.issued | 2018-04-18 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.uri | http://hdl.handle.net/2433/234208 | - |
dc.description.abstract | Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy. Although many types of VEGF pathway inhibitors can improve survival in most cancer patients, some patients have little or no beneficial effect from them. The primary or acquired resistance towards many oncological drugs, including anti-VEGF inhibitors, is a common problem in cancer treatment. This review summarizes the proposed alternative mechanisms of angiogenesis other than the VEGF pathway. These mechanisms are involved in the development of resistance to anti-VEGF therapies in cancer patients. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | en |
dc.rights | This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0). | en |
dc.subject | anti-angiogenic therapy | en |
dc.subject | resistance to anti-VEGF | en |
dc.subject | tumor microenvironment | en |
dc.title | Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway | en |
dc.type | journal article | - |
dc.type.niitype | Journal Article | - |
dc.identifier.jtitle | International Journal of Molecular Sciences | en |
dc.identifier.volume | 19 | - |
dc.identifier.issue | 4 | - |
dc.relation.doi | 10.3390/ijms19041232 | - |
dc.textversion | publisher | - |
dc.identifier.artnum | 1232 | - |
dc.address | Department of Surgery, Graduate School of Medicine, Kyoto University | en |
dc.address | Department of Surgery, Graduate School of Medicine, Kyoto University | en |
dc.address | Department of Surgery, Graduate School of Medicine, Kyoto University・Moores Cancer Center, University of California San Diego | en |
dc.address | Department of Surgery, Graduate School of Medicine, Kyoto University | en |
dc.identifier.pmid | 29670046 | - |
dcterms.accessRights | open access | - |
dc.identifier.eissn | 1422-0067 | - |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。